Estrella Immunopharma, Inc. (ESLA) Insider Trading Activity

NASDAQ$1.22
Market Cap
$51.28M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
564 of 883
Rank in Industry
336 of 506

ESLA Insider Trading Activity

ESLA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Insider Activity of Estrella Immunopharma, Inc.

Over the last 12 months, insiders at Estrella Immunopharma, Inc. have bought $0 and sold $0 worth of Estrella Immunopharma, Inc. stock.

On average, over the past 5 years, insiders at Estrella Immunopharma, Inc. have bought $44.68B and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 141,970 shares for transaction amount of $44.68B was made by Li Jianwei (Co‑Chief Executive Officer) on 2022‑03‑04.

List of Insider Buy and Sell Transactions, Estrella Immunopharma, Inc.

2022-03-04Purchase
Li Jianwei
Co-Chief Executive Officer
141,970
$314,700.00
$44.68B
+0.90%
Total: 1

ESLA Institutional Investors: Active Positions

Increased Positions14+175%357,595+48.12%
Decreased Positions3-37.5%51,176-6.89%
New Positions6New131,779New
Sold Out Positions2Sold Out4,016Sold Out
Total Postitions19+137.5%1M+41.23%

ESLA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$583.001.11%419,711+136,868+48.39%2025-09-30
Geode Capital Management, Llc$141.000.27%101,490-1,847-1.79%2025-09-30
Ubs Group Ag$70.000.13%50,347-22,426-30.82%2025-09-30
Citadel Advisors Llc$70.000.13%50,122-34-0.07%2025-09-30
Atw Spac Management Llc$56.000.11%40,00000%2025-09-30
Blackrock, Inc.$33.000.06%24,084-7,323-23.32%2025-09-30
State Street Corp$31.000.06%22,35200%2025-09-30
Renaissance Technologies Llc$15.000.03%10,689+10,689New2025-09-30
Xtx Topco Ltd$14.000.03%10,373+10,373New2025-09-30
Maso Capital Partners Ltd$14.000.03%10,00000%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.